Literature DB >> 9334522

Psychometric properties of the K-SADS-PL in an Israeli adolescent clinical population.

N Shanee1, A Apter, A Weizman.   

Abstract

The main objective of this study was to evaluate the reliability and validity of the Schedule for Affective-Disorders and Schizophrenia for School-Aged Children Lifetime Version (K-SADS-PL) in an Israeli sample. Fifty-seven adolescent admissions to two psychiatric units were evaluated with the Hebrew translation of the K-SADS-PL. Inter-rater and mother-child agreement were evaluated for diagnoses, and 31 affective symptoms. K-SADS diagnoses were also compared with two-month unit evaluation diagnoses as a measure of consensual validity. The reliability of assessing psychosocial functioning was also examined. Reliability and validity of diagnoses were good to excellent. Mother-child agreement fared less well on all measures. The use of semi-structured interviews and DSM-IV criteria in an Israeli adolescent psychiatric setting are discussed.

Entities:  

Mesh:

Year:  1997        PMID: 9334522

Source DB:  PubMed          Journal:  Isr J Psychiatry Relat Sci        ISSN: 0333-7308            Impact factor:   0.481


  28 in total

1.  Altered affinity of the platelet vesicular monoamine transporter 2 to dihydrotetrabenazine in children with major depression.

Authors:  Gil Zalsman; Moshe Rehavi; Netta Roz; Nathaniel Laor; Abraham Weizman; Paz Toren
Journal:  J Neural Transm (Vienna)       Date:  2011-04-12       Impact factor: 3.575

2.  Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders.

Authors:  Maya Amitai; Sefi Kronenberg; Miri Carmel; Elena Michaelovsky; Amos Frisch; David Brent; Alan Apter; Alon Chen; Abraham Weizman; Silvana Fennig
Journal:  J Neural Transm (Vienna)       Date:  2016-06-20       Impact factor: 3.575

3.  Validation of a Brief Structured Interview: The Children's Interview for Psychiatric Syndromes (ChIPS).

Authors:  Matthew E Young; Ziv E Bell; Mary A Fristad
Journal:  J Clin Psychol Med Settings       Date:  2016-12

4.  Parent and child acceptability and staff evaluation of K-SADS-PL: a pilot study.

Authors:  Merete Juul Sørensen; Per Hove Thomsen; Niels Bilenberg
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-05-02       Impact factor: 4.785

5.  Convergent validity of K-SADS-PL by comparison with CBCL in a Portuguese speaking outpatient population.

Authors:  Heloisa H A Brasil; Isabel A Bordin
Journal:  BMC Psychiatry       Date:  2010-10-19       Impact factor: 3.630

6.  Psychiatric morbidity with focus on obsessive-compulsive disorder in an Israeli cohort of adolescents with mild to moderate mental retardation.

Authors:  Doron Gothelf; Olga Goraly; Sari Avni; Mike Stawski; Inbar Hartmann; Lina Basel-Vanagaite; Alan Apter
Journal:  J Neural Transm (Vienna)       Date:  2008-03-20       Impact factor: 3.575

7.  Meta-analyses of agreement between diagnoses made from clinical evaluations and standardized diagnostic interviews.

Authors:  David C Rettew; Alicia Doyle Lynch; Thomas M Achenbach; Levent Dumenci; Masha Y Ivanova
Journal:  Int J Methods Psychiatr Res       Date:  2009-09       Impact factor: 4.035

8.  Is onset of Tourette syndrome influenced by life events?

Authors:  Netta Horesh; Sharon Zimmerman; Tami Steinberg; Haim Yagan; Alan Apter
Journal:  J Neural Transm (Vienna)       Date:  2008-01-24       Impact factor: 3.575

9.  Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study.

Authors:  Shella Schirman; Sefi Kronenberg; Alan Apter; David Brent; Nadine Melhem; Nimrod Pick; Miri Carmel; Amos Frisch; Abraham Weizman; Doron Gothelf
Journal:  J Neural Transm (Vienna)       Date:  2009-10-23       Impact factor: 3.575

10.  Cognition, psychosocial adjustment and coping in familial cases of velocardiofacial syndrome.

Authors:  D Gothelf; A Aviram-Goldring; M Burg; T Steinberg; M Mahajnah; A Frisch; S Fennig; G Zalsman; A Weizman
Journal:  J Neural Transm (Vienna)       Date:  2007-06-08       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.